Gastro Update-eMediNews:Health & Medicine Updates

Thursday, June 20, 2013 | Updated 12:35 IST

http://www.heartcarefoundationofindia.org/

https://www.facebook.com/pages/World-Fellowship-of-Religions/187532511301936

eMedinewS

NIH study to test treatment for fatty liver disease in children

NIH researchers are working to determine whether treating children diagnosed with severe fatty liver disease with a drug called cysteamine will help improve the liver.More...

Now LINX Reflux Management System

The US Food and Drug Administration’s Gastroenterology and Urology Devices Advisory Panel has voted unanimously to endorse the approval of the LINX Reflux Management System
More...

NIH study to test treatment for fatty liver disease in children

NIH researchers are working to determine whether treating children diagnosed with severe fatty liver disease with a drug called cysteamine will help improve the liver.
More...

Enoxaparin Ups Survival in Cirrhotic Portal Vein Thrombosis

A new treatment regimen with the low-molecular-weight heparin enoxaparin reduced the incidence of portal vein thrombosis (PVT), leading to fewer events of clinical decompensation and
More...

Other Gastro Update Article

Gastro news
Rifaximin for IBS: Irritable bowel syndrome (IBS) affects 10%-20% of the population. A lot of interest has focused recently on the potential microflora of the gut being 1 of the key factors causing IBS More »

Rifaximin for IBS: Irritable bowel syndrome (IBS)
Rifaximin for IBS: Irritable bowel syndrome (IBS) affects 10%-20% of the population. A lot of interest has focused recently on the potential microflora of the gut being 1 of the key factors causing IBS symptoms. The most promising studies have involved rifaximin, a poorly absorbed antibiotic that has More »